胰腺癌的蛋白质组学研究进展

Proteomics of pancreatic cancer

胰腺癌高居于癌症致死病的第四位,诊断后5年生存率小于5%,需要寻找新型生物标志物来提高早期诊断,并发现有效的治疗新靶点。蛋白质组学技术的发展提供了更好的分辨率和灵敏度,有助于在蛋白水平上更好地理解肿瘤发病机制,进而提高早期诊断和治疗的能力。近来在胰腺组织、胰液、血清、血浆、细胞株的蛋白质组学诸多研究鉴定了胰腺癌的差异表达蛋白,并发现新的潜在诊断生物标志物。本文就近年来胰腺癌的蛋白质组学研究结果及局限性做一综述。

Pancreatic cancer（PC） ranks at the fourth most common cancer-related mortality,and the 5-year survival rate is less than 5%.New biomarkers are needed to improve early diagnosis and develop new effective therapeutic targets.With the development of quantitative proteomics technologies,proteomics technology with better resolution and sensitivity will greatly enhance our capability in understanding the complex molecular events of tumorigenesis at the protein level.Proteomic studies of pancreatic tissues,juice,serum/plasma and cell lines have identified differentially expressed proteins in pancreatic cancer,and some proteome-based biomarkers can be used for early cancer detection.This article reviewed the results and limitation of proteomic studies of PC in recent years.